Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 18/20 | 0.54 |
| ▸ | UBA3 | Q8TBC4 | 16/20 | 0.54 |
| ▸ | UBA6 | A0AVT1 | 2/20 | 0.43 |
| ▸ | SAE1 | Q9UBE0 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | GRK5 | P34947 | 1/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.42 |
| ▸ | NEDD8 | Q15843 | 1/20 | 0.42 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL782844 | 0.89 | NAE1 (0.57) | NAE1UBA3UBA6SAE1 | |
| SCHEMBL782906 | 0.84 | NAE1 (0.54) | NAE1UBA3 | |
| SCHEMBL18540615 | 0.84 | NAE1 (0.67) | NAE1UBA3UBA6SAE1CA2 | |
| SCHEMBL17520035 | 0.84 | NAE1 (0.54) | NAE1UBA3 | |
| SCHEMBL12453391 | 0.83 | NAE1 (0.49) | NAE1UBA3 | |
| SCHEMBL805410 | 0.82 | NAE1 (0.44) | NAE1UBA3UBA6SAE1CA2 | |
| SCHEMBL783690 | 0.81 | NAE1 (0.59) | NAE1UBA3 | |
| SCHEMBL783623 | 0.81 | NAE1 (0.59) | NAE1UBA3 | |
| SCHEMBL12392783 | 0.81 | NAE1 (0.59) | NAE1UBA3 | |
| SCHEMBL802413 | 0.78 | NAE1 (0.78) | NAE1UBA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050935-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050935-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | RCE1, ECE1, UBE2E1 | NAE1 24/4885UBA3 6/4885UBA6 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.